The Enterprise DG of the European Commission retained Charles River Associates to undertake a study investigating whether there is a worldwide crisis in innovation in the pharmaceutical sector, the reasons behind this crisis, and the tools available to kick-start innovation.
Rare disease PMA trends in France: Price achieved vs. disease prevalence
In this installment, we examine the relationship between launch prices in France and disease prevalence as reported in the Haute Autorité de Santé assessments.